Meeting
2014 ASCO Annual Meeting
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.
Authors
Kevin Kalinsky
Columbia University Medical Center, New York, NY
Kevin Kalinsky , Dow-Chung Chi , Shing Mirn Lee , Kerin B. Adelson , Katherine D. Crew , Ellen Chuang , Della Makower , Dawn L. Hershman , Andrea Califano , Jose Silva , Matthew A. Maurer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS666)
DOI
10.1200/jco.2014.32.15_suppl.tps666
Abstract #
TPS666
Poster Bd #
123A
Abstract Disclosures
Similar Posters
First Author: Nicholas Patrick McAndrew
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).
First Author: Haeseong Park
Poster
2016 ASCO Annual Meeting
Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.
First Author: Bora Lim
Poster
2023 ASCO Annual Meeting
Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).
First Author: Hyo S. Han